Retatrutide and Fertility

Short answer: There is no human evidence that retatrutide impairs fertility, ovulation, sperm production, or the reproductive hormone axis. The trials simply did not measure those outcomes. The genuine, documented concern is the opposite of "infertility": retatrutide is unsafe to take while pregnant or trying to conceive, and weight loss on this class of drug may even make an unplanned pregnancy more likely. Those are two different questions, and the fear around fertility usually comes from blurring them together. None of what follows is medical advice; decisions about timing, contraception, and conception belong with your own clinician.

Does retatrutide affect fertility? What we know versus what we do not

When people ask whether retatrutide "affects fertility," they usually mean one of two things: does the drug damage the machinery that lets you conceive, or is it dangerous to be on while pregnant. The honest separation matters because the answers point in opposite directions.

On the first question, the machinery of fertility, there is no human data showing that retatrutide harms it. No published trial has reported reduced ovulation, lower sperm counts, suppressed sex hormones, or any other signal of reproductive impairment in people taking it. That is not the same as a clean bill of health, because the absence of a finding can mean the question was never asked. It was not asked here. Retatrutide is an investigational triple agonist (it activates the GLP-1, GIP, and glucagon receptors), and you can read more about how that works in our retatrutide mechanism of action explainer.

On the second question, pregnancy exposure, the data and regulatory guidance for the broader incretin class are clear and cautious: do not use these drugs during pregnancy, and stop well before trying to conceive. That is the concern worth taking seriously, and it is not a fertility concern at all.

"Infertility" versus "unsafe in pregnancy": the conflation driving the fear

A drug can be perfectly compatible with a working reproductive system and still be the wrong thing to have in your body once you are pregnant. Those are unrelated properties. Retatrutide sits in exactly that position.

"Impairs fertility" would mean the drug stops you from being able to conceive: it interferes with ovulation, with sperm, or with the hormonal signaling between brain and gonads. Nothing in the human record suggests retatrutide does this. "Unsafe in pregnancy" means that once a pregnancy exists, continued exposure could harm the developing fetus, and that rapid weight loss provides no benefit to a pregnant person. That is the established class position.

The two get fused because the practical advice ("do not be on this drug when you are trying for a baby") sounds, to an anxious reader, like a warning that the drug ruins fertility. It is not. It is a warning about exposure timing. Keeping the distinction straight is the single most useful thing you can take from this article.

What the retatrutide trials actually measured

The pivotal Phase 2 study is Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. It was a double-blind, randomized, placebo-controlled trial in 338 adults with obesity (BMI of 30 or higher, or 27 to 29.9 with a weight-related condition). Participants received subcutaneous retatrutide once weekly at 1, 4, 8, or 12 mg, or placebo, for 48 weeks. The primary endpoint was the percentage change in body weight from baseline to 24 weeks (Jastreboff et al., NEJM 2023, PMID 37366315).

The weight-loss results were large. At the highest dose, mean body weight fell by about 17.5% at 24 weeks and 24.2% at 48 weeks, versus roughly 2.1% on placebo at 48 weeks. The most common adverse events were gastrointestinal, dose-related, and mostly mild to moderate (PMID 37366315).

Here is the part that bears directly on the fertility question:

The larger Phase 3 program, TRIUMPH, was designed around weight, cardiovascular, and kidney outcomes in adults with obesity, not reproductive endpoints. So when anyone claims retatrutide "is known to" help or harm fertility, ask where the data is. For the metabolic effects that were measured, see our retatrutide side effects overview.

How weight loss restores ovulation in PCOS and obesity-related anovulation

This is where the picture flips from neutral to potentially favorable, at least by mechanism. Excess weight is a leading cause of anovulatory infertility, and losing a relatively modest amount of it often restores ovulation. The American Society for Reproductive Medicine notes that weight loss in women with obesity improves ovulatory function and reproductive outcomes (ASRM, Obesity and Reproduction Committee Opinion, 2021). A commonly cited figure is that losing roughly 5 to 10% of body weight can regularize cycles and restore spontaneous ovulation in anovulatory women with obesity; in one classic program, the large majority of anovulatory women who lost weight resumed ovulating and many conceived (Clark et al. / obesity and fertility outcomes, PMC2970793).

Retatrutide produces weight loss far above that 5 to 10% threshold. By the logic of the obesity-anovulation literature, that degree of weight loss would be expected to help, not hinder, ovulation in many women, although this has not been tested for retatrutide specifically.

Class data from GLP-1 receptor agonists supports the same direction. In women with polycystic ovary syndrome (PCOS), GLP-1 based therapies have been associated with improved menstrual regularity and ovulation, reductions in total and free testosterone, increases in SHBG, and improved insulin resistance (GLP-1 receptor agonists in PCOS, narrative review, PMC11949528). We cover this in depth in our pages on retatrutide for PCOS and GLP-1 benefits for women. The important caveats: this is class data and observational signal, not retatrutide-specific proof, and improving ovulation is exactly why an unintended pregnancy can happen, which is the next problem.

The "Ozempic baby" phenomenon and what it means on retatrutide

The "Ozempic baby" stories describe women who became pregnant unexpectedly after starting a GLP-1 drug, often despite using contraception they thought was reliable. There are two plausible drivers, and both apply in principle to retatrutide.

First, restored fertility. If weight loss brings back ovulation in someone who was anovulatory, conception becomes possible again, sometimes before that person realizes their cycles have changed. This is fertility working, not failing.

Second, contraceptive failure related to the drug. These medicines slow gastric emptying, which can affect how oral drugs (including the pill) are absorbed, and the gastrointestinal side effects common during dose escalation, vomiting and diarrhea, can cause missed or incompletely absorbed pills the ordinary way.

The practical upshot for anyone on retatrutide who does not want to conceive: do not assume your existing contraception is bulletproof during dose changes, and talk to your clinician about a backup method. More context on weight-loss effects in women is in our retatrutide for women guide.

Retatrutide and birth control: oral pills, gastric emptying, and safer backups

Like other incretin drugs, retatrutide delays gastric emptying. The semaglutide label states plainly that the drug "causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications" (Wegovy/semaglutide FDA label, DailyMed). Dedicated semaglutide interaction studies did not show a clinically meaningful change in absorption for the medications tested, but retatrutide is a different molecule with no published oral-contraceptive interaction study, and the gastrointestinal side effects during escalation are a separate, real route to pill failure.

The takeaway, to discuss with your care team rather than act on alone: non-oral, long-acting methods (IUD, implant, injection) bypass the gut entirely and are reasonable backups while you titrate or if you are having GI symptoms. This is contraceptive planning, not a fertility verdict.

Male fertility: testosterone, SHBG, sperm parameters, and weight loss in men

The Phase 2 trial was slightly more than half men, yet it reported no sperm or reproductive endpoints, so there is no direct retatrutide male-fertility data. What we can say is mechanistic and drawn from the broader obesity and GLP-1 literature.

Obesity in men is associated with lower testosterone, partly because adipose tissue converts testosterone to estrogen and lowers SHBG. Weight loss in men with obesity tends to raise testosterone and SHBG and can improve some semen parameters. GLP-1 based weight loss would be expected to move in the same favorable direction by reducing fat mass, though this is reasoning from the class and from obesity physiology rather than retatrutide-specific trial proof. As with women, the honest framing is "no signal of harm, plausible benefit through weight loss, no dedicated data."

Animal reproductive toxicology and why retatrutide is contraindicated in pregnancy and breastfeeding

For the GLP-1 class, animal reproduction studies have shown adverse effects on the developing fetus at clinically relevant exposures, which is the basis for the strong pregnancy warnings. The semaglutide label states that "weight loss offers no benefit to a pregnant patient and may cause fetal harm" and directs clinicians to advise pregnant patients of fetal risk and discontinue the drug when a pregnancy is recognized (Wegovy/semaglutide FDA label, DailyMed).

Two principles carry over to retatrutide. One, intentional weight loss during pregnancy is undesirable regardless of the drug, because pregnancy is a time for appropriate weight gain, not loss. Two, the animal-signal precaution that governs the established drugs applies with even more force to an investigational triple agonist that has no human pregnancy safety data at all. For these reasons retatrutide should be treated as contraindicated in pregnancy and during breastfeeding (incretin labels in this class recommend against breastfeeding given metabolite presence in milk and unknown infant risk). Our GLP-1 and pregnancy page covers this class-wide guidance in more detail.

How long before trying to conceive should you stop retatrutide?

This is a washout question, and it turns on half-life. Retatrutide has a mean elimination half-life of roughly 6 days, which is what allows once-weekly dosing (retatrutide pharmacotherapy review, PMC12190491). A drug is generally considered largely cleared after about five half-lives, so the body needs several weeks after the last dose to clear most of it; the deeper pharmacokinetics are in our retatrutide half-life explainer.

Regulators have translated similar math into concrete advice for the approved drugs. The semaglutide label instructs clinicians to "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide" (Wegovy/semaglutide FDA label, DailyMed).

Because retatrutide is investigational and has no pregnancy label of its own, there is no official washout number for it. A sensible, clinician-guided approach is to apply at least the same several-week-to-two-month buffer used for semaglutide. Do not improvise this on your own; the right stop date depends on your dose, your cycle, and your fertility plan, and that is a conversation for your prescriber.

What the data still cannot rule out

Honesty about the limits matters in a topic this loaded. Several things remain genuinely unknown:

• No reproductive endpoints were studied. The retatrutide trials did not measure ovulation, sperm, sex hormones, time to pregnancy, or pregnancy outcomes, so "no evidence of harm" reflects an absence of testing, not a tested absence of effect.
• No human pregnancy safety data. Because pregnancy was an exclusion criterion, there is no human dataset on first-trimester exposure to retatrutide.
• Class data is not retatrutide data. The favorable PCOS and male-weight-loss signals come from other GLP-1 drugs. Retatrutide also hits the glucagon receptor, which those drugs do not, and the reproductive implications of that have not been characterized.
• The "Ozempic baby" effect is described, not quantified for retatrutide. We can explain the mechanism, but there is no incidence rate for unintended pregnancy specifically on retatrutide.
• No oral-contraceptive interaction study in humans. The absorption question is inferred from class behavior, not measured for this molecule.

The bottom line is consistent with where we started. There is no evidence retatrutide harms fertility, good mechanistic reason to think weight loss can help ovulation in many people, and a clear, non-negotiable rule to be off the drug well before and during any pregnancy. Anything beyond that, especially timing and contraception decisions, should be worked out with your own clinician.

Frequently Asked Questions

Does retatrutide cause infertility?

There is no human evidence that retatrutide causes infertility. No published trial has reported reduced ovulation, lower sperm counts, or suppressed reproductive hormones. The reason it is restricted around pregnancy is fetal-exposure safety, not damage to your ability to conceive. Those are different issues that often get confused.

Can retatrutide help me get pregnant if I have PCOS or obesity?

Possibly, but indirectly and unproven for retatrutide specifically. In obesity-related anovulation, losing about 5 to 10% of body weight can restore ovulation, and GLP-1 class drugs have improved menstrual regularity and ovulation in PCOS (ASRM 2021; GLP-1 in PCOS review). The catch is that you must stop the drug before trying to conceive, so any fertility benefit comes from the weight you have lost, not from being on it while pregnant. Discuss a plan with your clinician.

How long before trying to conceive should I stop retatrutide?

Retatrutide's half-life is about 6 days, and the comparable approved drug semaglutide is labeled to be stopped at least 2 months before a planned pregnancy (Wegovy label). There is no official washout for investigational retatrutide, so a precautionary buffer of at least several weeks to two months, decided with your prescriber, is reasonable.

Will retatrutide make my birth control pill stop working?

It might reduce reliability, mainly during dose escalation. The drug slows gastric emptying and can cause vomiting and diarrhea, both of which can interfere with absorbing an oral pill (Wegovy label). Methods that bypass the gut, such as an IUD, implant, or injection, are not affected this way and are often suggested as backups. This is a contraception-planning question for your clinician.

Does retatrutide lower testosterone or harm sperm in men?

There is no retatrutide-specific data on testosterone or sperm. By mechanism, losing weight tends to raise testosterone and SHBG and may improve some semen parameters in men with obesity, so the expected direction is neutral to favorable rather than harmful. This remains reasoning from the class, not proof for retatrutide.

Is it safe to breastfeed while taking retatrutide?

It should be treated as not recommended. Incretin labels in this class advise against breastfeeding because of drug or metabolite presence in milk and unknown risk to the infant, and retatrutide has no human lactation safety data at all. If you are breastfeeding and considering retatrutide, raise it with your clinician before starting.